1 day Ago By Defense World Staff
Arizona State Retirement System boosted its position in AtriCure, Inc. ( NASDAQ:ATRC – Free Report ) by 4.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
The fund owned 13,542 shares of the medical device company’s stock after buying an additional 517 shares during the period. Arizona State Retirement System’s holdings in AtriCure were worth $308,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently bought and sold shares of ATRC.
Champlain Investment Partners LLC grew its position in AtriCure by 27.3% in the 1st quarter. Champlain Investment Partners LLC now owns 2,681,000 shares of the medical device company’s stock valued at $81,556,000 after buying an additional 575,605 shares during the last quarter.
Natixis acquired a new stake in AtriCure in the first quarter valued at $9,126,000. Norges Bank acquired a new stake in AtriCure in the fourth quarter valued at $9,254,000. Wasatch Advisors LP lifted its holdings in AtriCure by 38.
6% in the first quarter. Wasatch Advisors LP now owns 720,677 shares of the medical device company’s stock valued at $21,923,000 after acquiring an additional 200,799 shares during the period. Finally, Kennedy Capital Management LLC lifted its holdings in AtriCure by 115.
5% in the first quarter. Kennedy Capital Management LLC now owns 227,193 shares of the medical device company’s stock valued at $6,911,000 after acquiring an additional 121,752 shares during the period. 99.
11% of the stock is currently owned by hedge funds and other institutional investors. Analysts Set New Price Targets ATRC has been the subject of a number of recent analyst reports. BTIG Research reduced their target price on AtriCure from $58.
00 to $53.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. StockNews.
com raised AtriCure from a “sell” rating to a “hold” rating in a research note on Saturday. Stifel Nicolaus cut their price target on AtriCure from $30.00 to $26.
00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. JPMorgan Chase & Co. cut their price target on AtriCure from $34.
00 to $30.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Finally, Needham & Company LLC cut their price target on AtriCure from $40.
00 to $34.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock.
According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.44. AtriCure Stock Performance Shares of ATRC opened at $28.
07 on Wednesday. The business’s 50 day moving average is $24.22 and its two-hundred day moving average is $24.
82. AtriCure, Inc. has a 52-week low of $18.
94 and a 52-week high of $44.64. The firm has a market cap of $1.
34 billion, a price-to-earnings ratio of -35.09 and a beta of 1.43.
The company has a quick ratio of 2.93, a current ratio of 4.13 and a debt-to-equity ratio of 0.
16. AtriCure ( NASDAQ:ATRC – Get Free Report ) last announced its earnings results on Tuesday, July 30th. The medical device company reported ($0.
17) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.17). AtriCure had a negative return on equity of 8.
39% and a negative net margin of 9.33%. The company had revenue of $116.
27 million for the quarter, compared to analyst estimates of $116.24 million. During the same period in the prior year, the company posted ($0.
12) EPS. AtriCure’s quarterly revenue was up 15.2% on a year-over-year basis.
Analysts forecast that AtriCure, Inc. will post -0.77 EPS for the current fiscal year.
Insider Buying and Selling at AtriCure In related news, Director Maggie Yuen sold 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $24.07, for a total transaction of $84,245.
00. Following the sale, the director now directly owns 8,970 shares of the company’s stock, valued at approximately $215,907.90.
The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink . 3.20% of the stock is currently owned by corporate insiders.
AtriCure Company Profile ( Free Report ) AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. See Also Five stocks we like better than AtriCure Stock Dividend Cuts Happen Are You Ready? Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Roth IRA Calculator: Calculate Your Potential Returns Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge What Are Growth Stocks and Investing in Them Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for AtriCure, Inc. ( NASDAQ:ATRC – Free Report ). Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.
com's FREE daily email newsletter ..
